Do Density and XERF reduce cheek fat or a double chin?
A common explanation is that “XERF’s 2 MHz melts fat, so a double chin goes away”. This column separates where that explanation came from and what has actually been confirmed on human faces.
The short answer
As far as we could find, there are no human data showing that Density or XERF facial treatment reduces cheek or double-chin fat. The finding that XERF’s 2 MHz heats the fat layer broadly and deeply comes from computer simulation and porcine tissue, and most of its authors work for the manufacturer. In the United States a body-contouring device that claimed fat reduction as an indication had to submit clinical data, whereas the indication of XERF’s 510(k) was electrocoagulation and haemostasis. On the contrary, fat atrophy — excessive fat loss from RF heat, about 4 per 10,000 treatments — is classed as a side effect. The “lower-face thickness −0.89 mm” in the 16-person Density data is not a separate measurement of fat loss.
What are the data showing that XERF’s 2 MHz heats fat?
Of XERF’s two frequencies, 2 MHz heated the fat layer broadly and deeply in computer simulation and porcine skin histology, while 6.78 MHz heated locally along the fibrous septa (Lasers Med Sci 2025). The study was presented as the rationale for XERF’s two-frequency design; it did not measure whether fat decreased on human faces.
| Data | What was looked at | Limits |
|---|---|---|
| XERF frequency simulation · porcine tissue | Distribution of 2 MHz heating in the fat layer | Not a human study · most authors work for the manufacturer · one tip type only |
| XERF human studies, three (75 people) | Sagging and firmness assessment, pain | Fat thickness or volume not measured as an outcome |
| XERF US 510(k) K251327 | Indication electrocoagulation · haemostasis | No fat-reduction indication · no clinical data submitted |
Does Density’s “reduced lower-face thickness” mean fat was lost?
The 16-person Density case series (J Cosmet Dermatol 2025) reported a mean 0.89 mm reduction in lower-face tissue thickness on 3D imaging, but this value did not measure skin, fat and fascia separately. These Density data cannot distinguish tissue tightening that changed the contour from a reduction in fat itself, and there is no control group.
Turning “Density reduced thickness” into “Density removed fat” is an extension the data do not support.
What would XERF need in order to claim fat reduction?
In the US 510(k) system, what decides whether clinical data must be submitted is not the procedure but the size of the indication being claimed, and XERF did not claim fat reduction. The body-contouring device K180709 included fat and circumference reduction in its indication and submitted two prospective clinical studies. XERF’s K251327, by contrast, gave electrocoagulation and haemostasis as its indication and submitted no clinical data.
In other words, the fact that “XERF has FDA 510(k) clearance” tells you nothing about fat reduction — and 510(k) clearance is not FDA approval. In Korea, XERF is approved by the Ministry of Food and Drug Safety (MFDS, the national medical device regulator) in the general-purpose electrosurgical unit class.
Why fat loss from Density or XERF heat is a side effect, not a benefit
In RF lifting, including Density and XERF, fat atrophy — fat loss from excess heat — appears one to four months (mean two months) later as one sunken spot, and is a side effect reported at about 4 per 10,000 treatments. Facial fat is also a structure that supports the contour, so Miso Clinic does not design Density or XERF treatment to put in extra heat to shrink cheek fat.
| Concern | Role of Density or XERF | Consider first |
|---|---|---|
| Sagging under the jaw that looks like a double chin | Consider Density or XERF to tighten the sagging | Density · XERF · Oligio Kiss |
| A lot of fat under the jaw itself | No evidence Density or XERF reduces fat | Consultation on other treatments that address fat |
| Cheeks sagging so cheek fat has dropped | Consider Density or XERF for the sagging | Assess which layer is sagging |
| A lot of cheek fat making the face look wide | Density or XERF not recommended for fat reduction | A different consultation |
A 200-person ultrasound review found that sagging areas under the jaw had thinner skin and thicker superficial fat. Sagging and fat often occur together, so before Density or XERF we first separate which is the main cause.
Density, XERF and fat summary
What is established
- XERF 2 MHz heating in the fat layer — computer simulation · porcine tissue, authors employed by the manufacturer
- XERF 510(k) indication electrocoagulation · haemostasis, no fat-reduction indication
- Fat atrophy after RF such as Density and XERF is a side effect appearing at 1–4 months (about 4 per 10,000 treatments)
What we could not find
- A human study measuring fat thickness or volume after Density or XERF facial treatment
- A Density or XERF study with double-chin fat reduction as an outcome
- How much of Density’s lower-face thickness reduction is due to fat
Density, XERF and fat: frequently asked questions
Can XERF get rid of double-chin fat?
We could not find human data showing that XERF facial treatment reduces fat under the jaw. XERF’s 2 MHz fat-layer heating is a computer simulation and porcine tissue result. When sagging makes it look like a double chin, we consider XERF to tighten the sagging.
Does Density reduce cheek fat?
The 0.89 mm reduction in lower-face thickness in the 16-person Density data is not a measurement of fat alone, so it is not evidence that Density reduces cheek fat. Because of the risk of fat atrophy, Miso Clinic does not design Density treatment to add heat to shrink cheek fat.
Can the face hollow after RF lifting?
After RF lifting such as Density and XERF, fat atrophy rarely appears one to four months (mean two months) after treatment, reported at about 4 per 10,000 treatments. If one spot looks sunken, you should be seen early.
Has the FDA recognised XERF for fat reduction?
No. The indication of XERF’s 510(k) K251327 is electrocoagulation and haemostasis, no clinical data were submitted, and 510(k) clearance is not FDA approval. Another body-contouring device that claimed fat reduction as an indication did submit clinical data.
Read next
Product pages
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. Every study cited above is given together with its design, its size and the limitations the authors themselves recorded, and where we could not find data, we have said that we could not find any.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- XERF heating by frequency — Ko K et al., Lasers Med Sci 2025, PMID 41315066. Computer simulation · porcine tissue. 2 MHz heated the fat layer broadly and deeply; 6.78 MHz heated locally along the fibrous septa. Most authors work for the manufacturer, and it is not a human study.
- Density human data — Oku K, J Cosmet Dermatol 2025;24(10):e70504, PMID 41090512. The paper names DENSITY (Jeisys Medical) in the main text. 16 Japanese adults (1 man · 15 women, mean age 49.4 ± 6.1) · one session of about 500–600 shots · 24 weeks · no control group · single author. Tightening 0.82 mm, lower-face thickness −0.89 mm, GAIS improved in 15 of 16, pain 1.4/5, no burns, persistent erythema or scarring reported. The abstract (0.82 ± 0.36) and the main text (± 0.34) give different values.
- Three XERF human studies — Hwang JK, Medical Lasers 2025;14(1):23–30 (20 subjects · one session · 12 weeks) · Weiss RA et al., Cureus 2026;18(3):e104546, PMID 41930066 (39 subjects · two sessions · 90 days, manufacturer support) · Erlich G et al., Lasers Med Sci 2026;41(1), PMID 42611100 (retrospective, 16 subjects · one session · 3 months). None of the three has a control group.
- Fat-reduction indications and clinical submission — US 510(k) K180709 (a body-contouring device) included fat and circumference reduction in its indication and submitted two clinical studies. XERF’s K251327 has no such indication and submitted no clinical data.
- XERF US 510(k) — FDA K251327 (2025-08-11). The indication is electrocoagulation and haemostasis, and no clinical tests were submitted. In Korea the device is approved in the general-purpose electrosurgical unit class.
- Fat atrophy — Narins RS et al., Dermatol Surg 2006;32:115–124. Appears at 1–4 months (mean 2 months), about 4 per 10,000 treatments. Notes that heavy anaesthesia blocks pain feedback.
- Ultrasound of lower-face layers — Kwon SH et al., Dermatologic Surgery 2022;48(5):527–531, PMID 35093961. Retrospective review of 200 people. Sagging areas under the jaw had thinner skin and thicker superficial fat.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.